Neogen Corporation Revenue per Employee (NEOG), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Neogen Corporation  (NASDAQ: NEOG)
 

Neogen's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Neogen's Revenue per employee fell on a trailing twelve month basis to $ 330,118, but the productivity of Neogen's employees remained above the company average.
Within the Healthcare sector Employees of 288 other companies have achieved higher revenue per employee. While Neogen's total ranking has deteriorated compared to the previous quarter from 57 to 2358. Neogen has 2,636 employees.


What is Sales per Employee Ratio?







NEOG Revenue per Employee (May 31 2026)
IV. Quarter
(Feb 28 2026)
III. Quarter
(Nov 30 2025)
II. Quarter
(Aug 31 2025)
I. Quarter
(May 31 2025)
IV. Quarter
Y / Y Revenue Change -0.58 % -4.21 % -2.45 % -3.67 % -4.2 %
Sales per Employee (TTM) $ 330,118 330,618 334,133 336,275 339,293
NEOG's Total Ranking # 2358 # 57 # 36 # 23 # 225
Seq. Revenue Change 6.89 % -6.09 % 7.52 % -7.88 % 2.99 %


Revenue per Employee Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 289
Overall Market # 2358

Revenue per Employee Statistics
High Average Low
$ 351,893 $ 184,915 $ 69,820
(Feb 29 2024)   (May 31 2012)



Financial Statements
Neogen's Revenue MRQ $ 226 Millions Visit NEOG's Income Statement
Neogen's Revenues TTM $ 870 Millions Visit NEOG's aggregate revenue growth
What are NEOG's Sales? Visit NEOG's Sales by Segment


  News about Neogen Corporation Revenue per employee

Investor Alert Pomerantz Law Firm Investigates Potential Claims Against Neogen Corporation Amid Concerns of M...

New York, September 6, 2025 In a significant development for shareholders of Neogen Corporation (NASDAQ: NEOG), the Pomerantz Law Firm has announced that it is investigating potential claims on behalf of investors who may have suffered losses in their investment in the Company. This news comes as Neogen has been under scrutiny, prompting legal experts to assess whether the company’s actions may have led to breaches of fiduciary duty or other violations of investor rights.Neogen Corporation, a prominent player in food safety and animal health industries, has traditionally been recognized for its innovative products and services that help ensure the safety of food and animal products. However, recent events have raised concerns regarding its operational practices and financial reporting standards. The Pomerantz Law Firm’s proactive investigation is a response to these emerging uncertainties and seeks to assist investors seeking recourse for any potential damages incurred.




Other Ratios
Neogen's Income per Employee
Employees in In Vitro & In Vivo Diagnostic Substances
In Vitro & In Vivo Diagnostic Substances Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
NEOG's Revenue per Employee versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for NEOG's Competitors
Revenue per Employee for NEOG's Suppliers
Revenue per Employee for NEOG's Customers

You may also want to know
NEOG's Sales Growth Rates NEOG's Pe Price to earnings ratio NEOG's Receivables Turnover Ratio NEOG's Stock Quote
NEOG's Net Income Growth Rates NEOG's Ps Price to Sales ratio NEOG's Sales per Employee NEOG's Asset Turnover Ratio
NEOG's Net Margin NEOG's Pb Price to Book ratio NEOG's Financial Strength Ratios NEOG's Dividend Payout Ratio
Date modified: 2026-09-26T09:58:43+00:00




Companies with similar Revenue per Employee for 12 months ending May 31 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending May 31 2026Number of Employees May 31 2026
Macrogenics Inc   572,266.21 $ 167.674  Million 293 
Si bone inc   570,029.26 $ 214.331  Million 376 
Cardiff Lexington Corporation  567,380.00 $ 10.213  Million 18 
Insulet Corporation  565,444.44 $ 3,053.400  Million 5,400 
Novavax inc   552,464.62 $ 413.796  Million 749 
Embecta Corp   551,189.19 $ 1,019.700  Million 1,850 
Iridex Corp  548,860.22 $ 51.044  Million 93 
Henry Schein Inc   544,080.00 $ 13,602.000  Million 25,000 
Enanta Pharmaceuticals Inc  543,816.67 $ 65.258  Million 120 
Editas Medicine Inc   540,287.36 $ 47.005  Million 87 
Organogenesis Holdings Inc   535,660.42 $ 457.454  Million 854 
Bausch Health Companies Inc   534,630.54 $ 10,853.000  Million 20,300 
Instil Bio Inc   527,529.41 $ 8.968  Million 17 
Palatin Technologies Inc   527,401.24 $ 13.185  Million 25 
Globus Medical Inc   524,155.67 $ 3,144.934  Million 6,000 
10x Genomics Inc   523,400.68 $ 616.566  Million 1,178 
Ultragenyx Pharmaceutical Inc   523,130.56 $ 717.212  Million 1,371 
Iradimed Corporation  520,114.23 $ 86.339  Million 166 
Orthofix Medical Inc   519,217.45 $ 833.344  Million 1,605 
Lexicon Pharmaceuticals Inc   511,962.96 $ 41.469  Million 81 
Perrigo Company Plc  511,604.94 $ 4,144.000  Million 8,100 
Butterfly Network Inc   510,727.27 $ 112.360  Million 220 
Beone Medicines Ltd   510,686.50 $ 6,128.238  Million 12,000 
Elanco Animal Health Incorporated  507,070.71 $ 5,020.000  Million 9,900 
Alpha Pro Tech Ltd   505,723.58 $ 62.204  Million 123 
Angiodynamics Inc   502,731.01 $ 317.726  Million 632 
Zimmer Biomet Holdings Inc   500,517.65 $ 8,508.800  Million 17,000 
Biofrontera Inc   499,521.74 $ 45.956  Million 92 
Accuray Incorporated  495,467.24 $ 400.833  Million 809 
Resmed Inc   495,001.76 $ 5,628.170  Million 11,370 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.